Email updates

Keep up to date with the latest news and content from BMC Research Notes and BioMed Central.

Open Access Research article

Elevated serum leptin levels in patients with acute myocardial infarction; correlation with coronary angiographic and echocardiographic findings

Hadi AR Hadi Khafaji1, Abdul Bari Bener2, Nasser M Rizk3 and Jassim Al Suwaidi14*

Author Affiliations

1 Heart Hospital, Hamad Medical Corporation, Doha, Qatar

2 Dept. of Adult Cardiology, Dept. of Medical Statistics and Epidemiology, Doha, Qatar

3 Biomedical Department, Qatar University, Doha, Qatar, Heart Hospital, Hamad Medical Corporation, Qatar, Biomedical Department, Qatar University, Doha, Qatar

4 Department of Adult Cardiology Hamad Medical Corporation - Heart Hospital, P.O. Box 3050, Doha, Qatar

For all author emails, please log on.

BMC Research Notes 2012, 5:262  doi:10.1186/1756-0500-5-262

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1756-0500/5/262


Received:8 December 2011
Accepted:24 April 2012
Published:29 May 2012

© 2012 Khafaji et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

To assess the relationship between serial serum leptin levels in patients with acute myocardial infarction (AMI) who received thrombolysis and the degree of coronary atherosclerosis, coronary reperfusion, echocardiographic findings, and clinical outcome. 51 consecutive patients presenting with AMI were studied. Clinical characteristics including age, sex, body mass index (BMI) and cardiovascular risk factors were recorded. Serial serum leptin levels at the time of admission and subsequently at 0, 6, 12, 24, 36, 60 hours afterwards were obtained. Coronary angiography was performed in 34 patients; the relation between serum leptin levels and evidence of coronary reperfusion as well as the extent of coronary atherosclerosis according to the coronary artery surgery study classification (CASS) were evaluated. Echocardiographic evaluation was performed in all patients. 36 matched patients were enrolled as control group who had serum leptin level 9.4 ± 6.5 ng/ml.

Results

The patients mean age was 50.5 ± 10.6 years. There were 47 males and 3 females. 37.1% were diabetics, 23.5% were hypertensive, 21.6% were dyslipidemic and 22.7% were obese (BMI ≥ 30). Leptin concentrations (ng/ml) increased and peaked at the 4th sample (36 hrs) after admission (mean ± SD) sample (1) =9.55 ± 7.4, sample (2) =12.9 ± 8.4, sample (3) =13.8 ± 10.4, sample (4) =18.9 ± 18.1, sample (5) =11.4 ± 6.5, sample (6) =10.8 ± 8.9 ng/ml. There was a significant correlation between serum leptin and BMI (r = 0.342; p = 0.03). Leptin levels correlated significantly to creatine kinase level on the second day (r = 0.43, p ≤ 0.01). Significant correlation of mean serum leptin with the ejection fraction (P < 0.05) was found. No difference in timing of peak serum leptin between patients who achieved coronary reperfusion vs. those who did not (p = 0.8). There was a trend for an increase in the mean serum leptin levels with increasing number of diseased vessels. There was no correlation between serum leptin levels and outcome neither during the hospitalization nor at 9 months follow up.

Conclusion

Serum leptin levels increase after myocardial infarction. Serum leptin level may be a predictor of the left ventricular ejection fraction and the degree of atherosclerosis but not of coronary reperfusion.

Keywords:
Serum leptin; Acute myocardial infarction; Angiographic findings; Echocardiography

Background

Leptin is the 16,000 Dalton protein product of the obesity gene (ob) [1]. Leptin has a role in the body weight maintenance in humans. It is released into the blood stream, where it binds to leptin-binding protein and is transported into the cerebrospinal fluid [2-5] and exerts its major effect on the hypothalamus. The role of leptin in coronary artery vasoreactivity has been raised in a study by Sundell J et al. [6] in obese and non-obese patients, suggesting that leptin might have a role in the regulation of the myocardial blood flow. A preliminary study in a small number of patients suggested that leptin levels might increase with acute myocardial infarction [7]. Leptin is found to have multiple roles in the cardiovascular system. A number of investigators suggested its role as a vasoactive substance [7]. There is also some evidence that leptin may have a role in obesity-related hypertension [8]. In a human study, a correlation was seen between the serum concentration of leptin and blood pressure among patients with essential hypertension [9]. Leptin also may have a prothrombotic effect [10]. This effect appears to be mediated through the platelet leptin receptor. In a previous study we suggested that TNF alpha may represent a modulator of leptin action in the hypothalamus, such finding may have implication in the setting of acute myocardial infarction [11].

The aims of the current study were to evaluate serial levels of serum leptin among patients presenting with acute myocardial infarction (AMI) and whether there is a correlation between leptin and coronary reperfusion as well as with angiographic and echocardiographic data.

Methods

Study design

This study was conducted at Hamad General Hospital. 51 patients who were admitted to the Coronary Care Unit with a diagnosis of acute coronary syndrome (ACS) were studied; after written informed consent for participation in the study was obtained from participants. The definition of ACS in this study is according to the definition for acute myocardial infarction by the joint committee of American College of Cardiology/European Society of Cardiology [12]. Patients with major co-morbid conditions including renal failure were excluded from the study. Hamad Medical Corporation institutional review board approved the study.

Baseline clinical characteristics including age, sex, cardiovascular risk factors, and complete cardiovascular physical examination findings were recorded. The mode of administered therapy was also recorded. 49 patients with ST elevation myocardial infarction (STEMI) were given thrombolytic therapy with either metalyse, or streptokinase [13]. Tow patients suffered non-ST elevation myocardial infarction (NSTEMI). None of these patients developed acute complication such as cardiogenic shock or acute homodynamic disturbance. Height, weight, body mass index, smoking habit, alcohol intake, diabetes mellitus, hypertension, lipid profile including serum cholesterol, high density and low density lipoprotein, and serum creatinine of patients were analyzed. Measurements of serum creatinine kinase, creatinine kinase-MB portion, troponin T levels were taken at the time of admission (0 time) and subsequently at 6, 12, 24, 36, 60 hours afterwards. Full echocardiographic studies were performed for all patients on the 2nd day of admission. Variables including left ventricular ejection fraction (LV EF%), left ventricular end-systolic dimension (LVESD), left ventricular end-diastolic dimension (LVEDD), left atrial size, right ventricular dimension (RVD) and right ventricular systolic pressure (RVSP) were all recorded. Coronary angiography was performed in 36 patients as a routine clinical check up. Extent of diseased vessels involved; whether single vessel, two -vessel, or three-vessel diseases, and whether re-canalization achieved (defined non-invasively as rapid resolution of ST segment elevation reperfusion arrhythmias and chest pain resolution after thrombolytic therapy or angiographically by the evidence of non-occluded culprit coronary artery) were recorded.

36 matched (age and BMI) stable cardiac patients with the same age and sex were taken as a control group and their data were collected from the cardiology out patient department.

Biochemical analyses

Blood samples were collected in plain tubes from each patient at the time of admission and then at 6, 12, 24, 36, 48, 60 and 84 hours. All samples were separated and analyzed immediately with the exception of serum leptin. Aliquots for serum leptin were stored at −80 °C until the collection was completed. Leptin concentrations were measured by ELISA method. Linco Research, Inc USA supplied the reagents. The measuring range was 0.5–100 ng/ml. According to manufacturer the assay has high correlation with their radioimmunoassay for human leptin (r = 0.967), lower detection limit is 0.5 ng/ml and the concentration variations (CVs) at concentrations of 3.2 ng/ml & 8.18 ng/ml were 5% & 3.0% respectively [14]. Total cholesterol (TC), Triglycerides (TG) and HDL-cholesterol (HDL-C) were determined enzymatically by Hitachi 917, Roche, Mannheim, Germany. LDL- cholesterol (LDL-C) was estimated among those with TG concentrations < 4.5 mmol/l as TC - HDL-C - Tg/2.2 [15]. Those with TG >4.5 mmol/l were measured directly by reagents from the same manufacturer [16]. Between-run imprecision (CVs) for TC, TG & measured LDL- C were 3.0%, 4.0% 2.0% and 2.0% respectively. Troponin T & CKMB were measured immunochemically by Elecys 2010, Roche, according to the manufacturer protocols. Imprecision, between run (CVs), for troponin & CKMB were 2% & 3% respectively [17].

Normal fasting level of serum leptin

Normal fasting ranges for serum leptin are directly correlated with the degree of adiposity, with BMI range 18–25; serum leptin level for men (3.8 ± 1.8 ng/ml), and for women (7.4 ± 3.7 ng/ml). Serum leptin level rises approximately 2.5 times faster in women per unit BMI as compared to man. Keeping in mind that a diurnal rhythm of serum leptin concentrations, the values being 20 to 40 percent higher in the middle of the night as compared with daytime [18,19]. The peak shifts are in parallel with shifts in the timing of meals [20].

Coronary angiography and echocardiographic analysis

Coronary angiography was performed according to the standard Judkin technique femoral approach either on admission or during the recovery period. Several views of each coronary artery were analyzed. The severity of arterial stenosis (defined as maximal percent reduction in luminal diameter) was determined according to visual estimation using the coronary artery surgery study classification (CASS) study analysis. Significant coronary stenosis was defined as a 70% lumen narrowing or > than 50% lumen narrowing of the left main coronary artery. The extent of coronary artery disease was classified as 1, 2 or 3 vessels according to number of major coronary arteries with significant stenosis [21].

Transthoracic 2 dimensional echocardiography 3 megahertz, 5500 Hewlett Packard Sonos machine was used for the study. Images were captured in the 5 standard views, parasternal long axis views, short axis view and 4, 2 &3 chamber views according to criteria of American society of echocardiography. The measurement of left ventricular dimensions was performed from 2 dimensional targeted M-mode at end diastolic and end systolic dimensions and subsequently LV ejection fraction was calculated. Left atrial size at end systole was measured from the parasternal long axis view. Right ventricular dimensions were recorded from the parasternal long axis view. Conventional Doppler measurements were obtained using tricuspid inflow, mitral early and late diastolic inflow velocities, volumetric relaxation times were also recorded. Wall motion abnormalities were recorded using 16 segment models [22].

Statistical analysis

The data were analyzed by using the Statistical Packages for Social Sciences [SPSS] version 19 [23]. Data were expressed as mean and standard deviation (SD) unless otherwise stated; student t test was used to ascertain the significance of difference between mean values of two continuous variables and confirmed by non-parametric Mann Whitney test. Fisher exact and Chi square test were performed to test for difference in proportions of categorical variable between two and more groups. The Pearson’s correlation coefficient was used to evaluate the strength association between two variables. The level of P < 0.05 was considered as the cut off value for significance. Repeated measures ANOVA utilized to test differences in serial leptin measures.

Results

Baseline clinical characteristics of the studied patients shown in Table 1. The mean age of patients was 50.5 ± 10.6 years. There were 47 males and 4 females. 37.1% had diabetes mellitus, 23.5% had hypertension, 21.6% had high cholesterol, and 22.7% were obese (BMI ≥ 30). Thirty six matched (with age and BMI) stable cardiac patients were taken as a control group. The mean serum leptin level of the control group was 9.43 ± 6.5 ng/ml.

Table 1. Clinical baseline characteristics compared with mean and peak leptin sample

Table 2 shows echocardiographic and coronary angiographic characteristics compared with mean and peak serum leptin sample.

Table 2. Echocardiographic & coronary angiographic characteristics compared with mean and peak leptin sample

Figure 1 shows the mean values of serum leptin level during the course of AMI at different time points. Leptin concentrations (ng/ml) increased and peaked at fourth reading (36 hrs) after admission and gradually decreased thereafter (mean ± SD sample (1) =9.55 ± 7.4, sample (2) = 12.9 ± 8.4, sample (3) =13.8 ± 10.4, sample (4) =18.9 ± 18.1, sample (5) =11.4 ± 6.5, sample (6) =10.8 ± 8.9) ng/ml, P value 0.04 based on repeated measures ANOVA.

thumbnailFigure 1. Mean values of Serum leptin level (ng/ml) during the course of AMI at different time points (P value 0.04 based on repeated measures ANOVA).

There was a significant correlation between serum leptin and BMI (r = 0.34; p = 0.03). Leptin levels also correlated significantly with serum creatine kinase level on the second day (r = 0.43, p ≤ 0.01). There was no difference in timing of peak serum levels between patients who had evidence of coronary reperfusion compared to those who did not achieve coronary reperfusion (p = 0.8), also there was no significant difference in mean serum leptin level in patients with anterior MI vs. inferior MI (mean ± SD = 11.71 ± 7, 9 vs.11.86 ± 6.6 ng/ml, p = 0.9) respectively. However, there was significant correlation with left ventricular ejection fraction, LVEF (r = −0.25, p = 0.01). No significant correlation between mean serum leptin and left atrial size (r = −0.09; p = 0.5), left ventricular systolic (r = 0.017, p = 0.9) or diastolic dimension (r = 0.1; p = 0.47) were found.

Figure 2 shows that mean serum leptin, which appeared to increase with the increase in the number of diseased vessels (mean, SVD = 9.2, 2VD = 12.0, 3VD = 12.9, p = 0.6), although this was not statistically significant.

thumbnailFigure 2. Serum leptin level by number of diseased vessels (VD). (SVD = 9.2, 2VD = 12.0, 3VD = 12.9 ng/ml, p= 0.6).

Correlation between mean and peak leptin level and variables of interest showed significant correlation of mean serum leptin with the ejection fraction and body mass index (P < 0.05), and significant correlation of creatinine kinase with mean leptin level (P < 0.05) (Table 3).

Table 3. Correlation between mean Leptin level and variables of interest

Discussion

Studies on the role of serum leptin in coronary artery disease are scarce [24-34] (Table 4). To the best of our knowledge, this study is among few studies that analyzed the serial serum leptin levels in the setting of acute myocardial infarction and the first that evaluated its correlation with angiographic and echocardiographic findings in this high-risk group.

Table 4. Studies on leptin in acute myocardial infarction

In the United States population, increased leptin concentrations was significantly associated with increased risk of myocardial infarction and stroke in men and women, independent of traditional cardiovascular risk factors and obesity status [36]. We have shown previously a significant correlation between serum leptin and hs-CRP in stable cardiac patients [37]. Study by Stangl et al. [38] concluded that patients with coronary artery disease exhibited higher serum leptin concentrations than controls matched for age, gender & BMI, suggesting that leptin could contribute to the development of cardiovascular disease, possibly via activation of the sympathetic nervous system. The Trp64Arg variant of the β-adrenoceptor did not influence serum leptin levels [38]. Leptin might be a marker of risk of coronary artery disease, at least in men, and contributes to the risk profile in subjects with insulin resistance. Leptin concentrations were significantly higher in diabetic and coronary artery disease patients than in controls. Body weight, serum triglyceride concentration and systolic blood pressure were all significantly related to the logarithm of the serum leptin concentration in stable coronary artery disease patients [39]. Wallace et al. [40] documented that leptin is an independent risk factor for coronary artery disease using data from the west Scotland coronary prevention study. It has been suggests that leptin might participate in the catabolic state leading to development of cardiac cachexia in the course of congestive heart failure [41].

The current study demonstrates elevation of serum leptin levels in the acute phase of myocardial infarction and it peaks at 36 hours after admission (doubled). Whether leptin is released from the myocytes or it acts only as an acute phase reactant protein after its release from adipose tissue, was the main issue of this project. The fact that there was no earlier peak in serum leptin in patients who had coronary reperfusion after thrombolytic therapy compared to those who don’t achieve reperfusion suggests that leptin is not released from the myocytes and is mainly an acute phase reactant similar to high sensitivity C- reactive protein. This finding is concordant to the study in Poland, which included 35 patients with AMI and showed that plasma leptin levels in diabetic patients were significantly higher in AMI than in the period of convalescence. These findings suggest that leptin may play an important role in the metabolic changes taking place during the first days of AMI [24].

Correlating mean and peak serum leptin levels; serum leptin is positively correlated with the extent of diseased coronary vessels (1-, 2-, and 3 -vessel disease) (Figure 2), although statistically not significant, expanding the study sample may be confirmatory of this finding. Furthermore no significant correlation with either evidence of coronary re-canalization or with the type of MI (whether anterior or inferior) was found. We observed a significant correlation between serum leptin and LVEF with no significant correlation with other echocardiographic findings. Significant correlations were found between high serum leptin level and BMI as was demonstrated by previous studies (Table 3), with no significant correlation to other cardiovascular risk factor; diabetes, hypertension, total cholesterol LDL, HDL or triglyceride in this patients’ population. In contrast to our study which has followed the leptin up to 60 hours after the onset of AMI, investigators from Turkey studied the influence of plasma leptin concentrations obtained at the time of admission and 6 hours afterwards in 41 AMI patients who were treated with thrombolytic therapy. The investigators found that failure of reperfusion therapy with streptokinase was significantly higher in patients with admission plasma leptin concentrations ≥14 ng/mL as compared to patients with admission plasma leptin concentrations <14 ng/m, i.e. hyperleptinemia decreased the chance of successful reperfusion . Left ventricular ejection fraction was slightly but significantly higher in patients with admission plasma leptin concentrations ≥14 ng/mL than in patients with admission plasma leptin concentrations <14 ng/m (p = 0.031) [25]. Another study involving 30 consecutive AMI patients with a similar profile to the current one, showed that leptin levels reached its peak on the second day of hospitalization, with a 2-fold increase from baseline level on admission (p < 0.02). On day 3, leptin levels declined, and were 46%, 9%, and 6% above baseline on days 3, 4 and 5, respectively, suggesting that leptin may have a role in the metabolic changes taking place during the first days after an AMI. [26].

The predictive power of leptin on cardiovascular disease was addressed in a report from the Quebec cardiovascular study[27], eighty-six patients who developed ischemic heart disease were compared with referent matched for a number of traditional cardiovascular risk factor including body mass index. Leptin did not emerge as a predictor in coronary artery disease. However, fundamental differences between the two studies, first and most importantly, patients in our present study were all proven first ever AMI cases according to newly defined criteria [12], whereas in Quebec, the study group constituted a mixture of stable and unstable angina [27]. Furthermore Fujimaki et al. [35] correlated serum leptin with other myocardial infarction markers and interleukin level in 15 aged-matched controls and found a significant negative correlation between these two markers. These studies again suggest that leptin may play an important role in the metabolic changes taking place during the first days of myocardial infarction.

Limitations of the study

Since this study included a small number of patients, the result should be interpreted cautiously.

Conclusion

Serum leptin acts as an acute phase reactant in AMI patients. Significant correlation was found in mean serum leptin level with BMI, CK, and LVEF. There was no significant difference in mean serum leptin level in patients with anterior vs. inferior infarction and statistically no significant correlations of serum leptin with severity of angiographic findings and other echocardiographic parameters.

Abbreviations

BMI: body mass index; SVD: single vessel disease; 2VD: two vessel disease; 3VD: three vessel disease; LVEF: left ventricular ejection fraction; RVD: right ventricular dimension; RVSP: right ventricular systolic pressure; STEMI: ST elevation myocardial infarction.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

HARHK- participated in the design of the study, patients’ recruitment, writing, analyzing and reviewing the paper. AB- performed the statistical analysis. NR- participated in the design of the study and the performance of laboratory investigations. JA- participated in the design of the study and patients’ enrollment. All authors read and approved the final manuscript.

Acknowledgements

This study was funded by the Medical Research Center of Hamad Medical Corporation, Doha, Qatar [Grant No 263]. The study was conducted in collaboration with biomedical department of the Qatar University, Doha, Qatar. We sincerely acknowledge: Ms. Nora Basem and Mrs. Wafa Khalil for their laboratory work and their technical support in this study.

References

  1. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue.

    Nature 1994, 372:425. PubMed Abstract | Publisher Full Text OpenURL

  2. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM: Weight-reducing effects of the plasma protein encoded by the obese gene.

    Science 1995, 269:543. PubMed Abstract | Publisher Full Text OpenURL

  3. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F: Effects of the obese gene product on body weight regulation in ob/ob mice.

    Science 1995, 269:540. PubMed Abstract | Publisher Full Text OpenURL

  4. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P: Recombinant mouse ob protein: evidence for a peripheral signal linking adiposity and central neural networks.

    Science 1995, 269:546. PubMed Abstract | Publisher Full Text OpenURL

  5. Sharma K, Considine RV: The Ob protein (leptin) and the kidney.

    Kidney Int 1998, 53:1483. PubMed Abstract | Publisher Full Text OpenURL

  6. Sundell J, Huuppon R, Raitakari OT, Nuutila P, Knuuti J: High serum leptin is associated with attenuated coronary vasoreactivity.

    Obes Res 2003, 11(6):776-782. PubMed Abstract | Publisher Full Text OpenURL

  7. Matsuda K, Teragawa H, Fukuda Y, Nakagawa K, Higashi Y, Chayama K: Leptin causes nitric-oxide independent coronary artery vasodilation in humans.

    Hypertens Res 2003 Feb, 26(2):147-152. Publisher Full Text OpenURL

  8. Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, Matsuoka N, Hayashi T, Hosoda K, Inoue G, Yoshimasa Y, et al.: Pathophysiological role of leptin in obesity-related hypertension.

    J Clin Invest 2000, 105:1243. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  9. Agata J, Masuda A, Takada M, Higashiura K, Murakami H, Miyazaki Y, Shimamoto K: High plasma immunoreactive leptin level in essential hypertension.

    Am J Hypertens 1997, 10:1171. PubMed Abstract | Publisher Full Text OpenURL

  10. Bodary PF, Westrick RJ, Wickenheiser KJ, Shen Y, Eitzman DT: Effect of leptin on arterial thrombosis following vascular injury in mice.

    JAMA 2002, 287:1706. PubMed Abstract | Publisher Full Text OpenURL

  11. Rizk NM, Stammsen D, Preibisch G, Eckel J: Leptin and tumor necrosis factor-alpha induce the tyrosine phosphorylation of signal transducer and activator of transcription proteins in the hypothalamus of normal rats in vivo.

    Endocrinology 2001 Jul, 142(7):3027-3032. Publisher Full Text OpenURL

  12. Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction redefined –a consensus document of the Joint European Society of Cardiology/American College of cardiology Committee for redefinition of of myocardial infarction.

    J Am Coll Cardiol 2000, 36(3):959-973. PubMed Abstract | Publisher Full Text OpenURL

  13. Hadi HAR: Al Suwaidi J, Bener A, Al Binali H: Thrombolytic therapy use in acute myocardial infaction and outcome in Qatar, int J.

    Cardiol 2005, 102:249-254. OpenURL

  14. Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M: Radioimmunoassay of Leptin in Human Plasma.

    Clin Chem June 1996, 42:942-946. OpenURL

  15. Fridewald WF, Levy RI, Frederickson DS: Estimation of LDLcholesterol concentration without use of the Preparative Ultra-centrifuge.

    Clin Chem 1972, 18:499-502. PubMed Abstract | Publisher Full Text OpenURL

  16. Nauck M, Warnick GR, Rifai N: Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation.

    Clin Chem 2002, 48:236-254. PubMed Abstract | Publisher Full Text OpenURL

  17. Panteghini M, Pagani F: Yeo KTJ, Apple FS, Christenson RH, Dati F, Mair J, Ravkilde J.

    Wu AH: Committee on Standardization of Markers of Cardiac Damage of the IFCC. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004, 50:327-332. OpenURL

  18. Boden G, Chen X, Kolaczynski JW, Polansky M: Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects.

    J Clin Invest 1997, 100:1107. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  19. Licinio J, Negrao AB, Mantzoros C, Kaklamani V, Wong ML, Bongiorno PB, Mulla A, Cearnal L, Veldhuis JD, Flier JS, et al.: Synchronicity of frequently sampled, 24-h concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women.

    Proc Natl Acad Sci U S A 1998, 95:2541. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  20. Schoeller DA, Cella LK, Sinha MK, Caro JF: Entrainment of the diurnal rhythm of plasma leptin to meal timing.

    J Clin Invest 1882, 1997:100. OpenURL

  21. Rogers WJ, Coggin CJ, Gersh BJ, Fisher LD, Myers WO, Oberman A, Sheffield LT: Ten-year follow-up of quality of life in patients randomized to receive medical therapy or coronary artery bypass graft surgery: The Coronary Artery Surgical Study (CASS).

    Circulation 1990, 82:1647. PubMed Abstract | Publisher Full Text OpenURL

  22. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS: American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

    Circulation 2002, 105:539. PubMed Abstract | Publisher Full Text OpenURL

  23. Norusis MJ: SPSS/PC + for windows. Base System and Advanced Statistical User’s Guide, Window Version.

    Chicago, Illinois 1998., 12 OpenURL

  24. Krasnodebski P, Bak MI, Opolski G, Karnafel W: Leptin in acute myocardial infarction and period of convalescence in patients with type 2 diabetes mellitus.

    Kardiol Pol. 2010 Jun, 68(6):648-653. OpenURL

  25. Amasyali B, Aytemir K, Kose S, Kilic A, Abali G, Iyisoy A, Kursaklioglu H, Turan M, Bingol N, Isik E, et al.: Admission plasma leptin level strongly correlates with the success of thrombolytic therapy in patients with acute myocardial infarction.

    Angiology 2006, 57(6):671-680. PubMed Abstract | Publisher Full Text OpenURL

  26. Meisel SR, Ellis M, Pariente C, Pauzner H, Liebowitz M, David D, Shimon I: Serum leptin levels increase following acute myocardial infarction.

    Cardiology 2001, 95(4):206-211. PubMed Abstract | Publisher Full Text OpenURL

  27. Després JP, Lupien PJ, Moorjani S, Dagenais GR, Cantin B, Mauriege P, Lamarche B, Couillard C: Leptenemia is not a risk factor for ischemic heart disease in men. Prospective results from Quebec Cardiovascular study.

    Diabetic Care 1998, 21:782-786. Publisher Full Text OpenURL

  28. Yan GT, Xue H, Lin J, Hao XH, Zhang K, Wang LH: Correlation analysis of increase in serum level of leptin with that of C reactive protein, troponin T and endothelin in patients with acute myocardial infarction.

    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2005 Sep, 17(9):530-532. OpenURL

  29. Wallander M, Söderberg S, Norhammar A: Leptin: a predictor of abnormal glucose tolerance and prognosis in patients with myocardial infarction and without previously known Type 2 diabetes.

    Diabet Med 2008 Aug, 25(8):949-955. Publisher Full Text OpenURL

  30. Taneli F, Yegane S, Ulman C, Tikiz H, Bilge AR, Ari Z, Uyanik BS: Increased serum leptin concentrations in patients with chronic stable angina pectoris and ST-elevated myocardial infarction.

    Angiology 2006, 57(3):267-272. PubMed Abstract | Publisher Full Text OpenURL

  31. Piestrzeniewicz K, Luczak K, Komorowski J, Maciejewski M, Goch JH: The relationship between leptin and obesity and cardiovascular risk factors in men with acute myocardial infarction.

    Cardiol J. 2007, 14(3):252-259. PubMed Abstract | Publisher Full Text OpenURL

  32. Selvakumar D, Selvakumar PV, George P, Jose VJ Mariappan P: Serum leptin levels in acute myocardial infarction.

    Indian Heart J 2005, 57(1):39-43. PubMed Abstract OpenURL

  33. Söderberg S, Ahrén B, Jansson JH, Johnson O, Hallmans G, Asplund K, Olsson T: Leptin is associated with increased risk of myocardial infarction.

    J Intern Med. 1999 Oct, 246(4):409-418. Publisher Full Text OpenURL

  34. Stejskal D, Růzicka V, Bartek J, Horalík D: Leptinemia in persons with acute myocardial infarct.

    Vnitr Lek. 1998 Oct, 44(10):588-592. OpenURL

  35. Fujimaki S, Kanda T, Fujita K, Tamura J, Kobayashi I: The significance of measuring plasma leptin in acute myocardial infarction.

    J Int Med Res 2001, 29(2):108-113. PubMed Abstract | Publisher Full Text OpenURL

  36. Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F, Gami AS, Sert Kuniyoshi FH, Wolk R, Somers VK: Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population.

    Am J Cardiol 2007, 100(2):234-239. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  37. Khafaji HAR Hadi, Bener A, Osman M, Al-marri A, Al Suwaidi J: The impact of diurnal fasting during Ramadan on the lipid profile, hs-CRP, and serum leptin in stable cardiac patients.

    Vascular Health and Risk Management 2012, 8:7-14. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  38. Stangl K, Cascorbi I, Laule M, Stangl V, Vogt M, Ziemer S, Roots I, Wernecke K, Baumann G, Hauner H: Elevated serum leptin in patients with coronary artery disease: no association with the Trp64Arg polymorphism of the beta3-adrenergic receptor.

    Int J Obes Relat Metab Disord. 2000 Mar, 24(3):369-375. Publisher Full Text OpenURL

  39. Al-Daghri N, Al-Rubean K, Bartlett WA, Al-Attas O, Jones AF, Kumar S: Serum leptin is elevated in Saudi Arabian patients with metabolic syndrome and coronary artery disease.

    Diabet Med 2003 Oct, 20(10):832-837. Publisher Full Text OpenURL

  40. Wallace AM Mc Mahan AD, Packed CJ, Kelly A, Shepherd J, Gaw A, Sattar N: Plasma Leptin and the risk of cardiovascular disease in the wast of Scotland coronary prevention study.

    Circulation 2001, 104:3052-3056. PubMed Abstract | Publisher Full Text OpenURL

  41. Schuler G, Moebius-Winkler S, Erbs S, Gielen S, Adams V, Schoene N, Linke A, Kratzsch J, Schule PC: Elevated serum levels of leptin and soluble leptin receptor in patients with advanced heart failure.

    EurJ Heart Fail 2003., 33(1) OpenURL